

Bivalent HPV Vaccine Gets ACIP Recommendation

BY HEIDI SPLETE

ATLANTA — The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices recommended a bivalent human papillomavirus vaccine as an alternative to the quadrivalent vaccine for the prevention of cervical cancer and related precancerous conditions in women and girls aged 9-26 years.

ACIP made the recommendation at its annual fall meeting.

The bivalent human papillomavirus (HPV) vaccine (GlaxoSmithKline's Cervarix) was recently approved by the Food and Drug Administration. The vaccine provides clinicians with another option to vaccinate adolescent girls and young women against diseases caused by HPV types 16 and 18.

But unlike the quadrivalent vaccine, the bivalent vaccine is not designed to protect against genital warts, noted Dr. Lauri Markowitz of the CDC, who presented the ACIP recommendations for the use of the bivalent vaccine.

The quadrivalent vaccine (Merck & Co.'s Gardasil) protects against genital warts associated with HPV types 6 and 11, in addition to protecting against diseases caused by HPV types 16 and 18.

ACIP recommended against a statement of no preference between the bivalent and quadrivalent vaccines after a lively debate.

Instead, the recommendations will present the information about the two vaccines without a statement of preference or a statement of nonpreference. The recommendations state that the two vaccines can be used interchangeably to complete the three-dose series, but that using the same vaccine for the entire series is preferable.

The bivalent vaccine, like the quadrivalent vaccine, is not a live vaccine, and it can be given simultaneously with other vaccines.

ACIP also voted to harmonize the age ranges for the two vaccines, with first doses given at ages 11-12 years and recommended second and third doses at 1-2 months and 6 months after the first dose. The recommended minimum dosing intervals remained as 4 weeks between the first and second dose and 12 weeks between the second and third doses.

The vaccine can be initiated as young as 9 years, and catch-up vaccination is recommended for females aged 13-26 years.

In addition, ACIP voted to move information about pregnancy to the precautions section. Pregnancy is not currently a contraindication for the vaccine. But Dr. Frank DeStefano of the CDC's immunization safety office said that post-marketing safety surveillance studies would be conducted on the bivalent HPV vaccine using the Vaccine Adverse Event Reporting System (VAERS), including a study to look at pregnancy out-

comes after vaccination with the bivalent vaccine.

The committee voted to add the bivalent vaccine to the CDC's Vaccines for Children program. ■

For the latest information on ACIP vaccine recommendations, visit cdc.gov/vaccines/recs/acip.



PARKER SMITH/ELSEVIER GLOBAL MEDICAL NEWS

Unlike the quadrivalent vaccine, the bivalent vaccine is not designed to prevent genital warts, Dr. Lauri Markowitz said.

Research is vital to the advancement of patient care

That's why we exist.

We are the leading private funding source for skin disease research and career development of physicians and scientists.

To date, we have invested **\$50 million** in the specialty, and are second only to the federal government in supporting dermatologic research.

We provide research funding that helps develop and retain tomorrow's teachers and researchers in dermatology, and enables advancements in patient care.

Our support allows the best and brightest to stay on the academic and research career path, and realize improvements that all dermatologists can bring to their patients.

DF Dermatology
Foundation

SHAPING THE FUTURE OF DERMATOLOGY

www.dermatologyfoundation.org

Underwritten through an educational grant from Galderma Laboratories